Iblias

RSS

octocog alfa

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Iblias has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 18/02/2020

Authorisation details

Product details
Name
Iblias
Agency product number
EMEA/H/C/004147
Active substance
octocog alfa
International non-proprietary name (INN) or common name
octocog alfa
Therapeutic area (MeSH)
Hemophilia A
Anatomical therapeutic chemical (ATC) code
B02BD02
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Bayer AG
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
18/02/2016
Contact address

51368 Leverkusen 
Germany

Product information

10/11/2017 Iblias - EMEA/H/C/004147 - A31/0002

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Iblias can be used for all age groups.

Assessment history

How useful was this page?

Add your rating
Average
1 rating